Overall, most chronically ill children still die in hospitals, with African American and Hispanic individuals continuing to be less likely than white individuals to die in the home. However, the shifting trend in place of death raises queries for families, medical policy-manufacturers and caregivers about how exactly to best provide care and resources for very ill children. There has been a quiet transformation in care for children with severe chronic conditions, stated pediatrician Chris Feudtner, M.D., Ph.D., M.P.H., lead author of the study in the June 27 Journal of the American Medical Association.The advantage of ticagrelor on CV thrombotic occasions, including CV mortality, seen in patients who have experienced an ACS event facilitates continued research in the areas of coronary disease.’ The first scientific research of PARTHENON was PLATO . Ongoing research in PARTHENON will move beyond ACS, investigating the usage of ticagrelor as monotherapy and compared to additional oral antiplatelets. PEGASUS is normally a randomized, double-blind, parallel-group, international, multi-center study of around 21,000 patients across 31 countries. Sufferers are getting randomized to the 90 mg dosage or 60 mg dosage of ticagrelor BID or placebo.